TENOFOVIR ALAFENAMIDE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Tenofovir Alafenamide, and when can generic versions of Tenofovir Alafenamide launch?
Tenofovir Alafenamide is a drug marketed by Lupin Ltd and is included in one NDA.
The generic ingredient in TENOFOVIR ALAFENAMIDE is tenofovir alafenamide fumarate. There are forty-two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the tenofovir alafenamide fumarate profile page.
Summary for TENOFOVIR ALAFENAMIDE
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 63 |
| Clinical Trials: | 210 |
| Patent Applications: | 422 |
| DailyMed Link: | TENOFOVIR ALAFENAMIDE at DailyMed |
Recent Clinical Trials for TENOFOVIR ALAFENAMIDE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Chiang Mai University, Thailand | Phase 3 |
| Assistance Publique - Hôpitaux de Paris, FRANCE | Phase 3 |
| Ministry of Health, Thailand | Phase 3 |
Anatomical Therapeutic Chemical (ATC) Classes for TENOFOVIR ALAFENAMIDE
US Patents and Regulatory Information for TENOFOVIR ALAFENAMIDE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lupin Ltd | TENOFOVIR ALAFENAMIDE | tenofovir alafenamide fumarate | TABLET;ORAL | 214226-001 | Mar 30, 2023 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
